Hypertrophic cardiomyopathy in black vs white patients may be associated with a greater burden of functional heart failure and reduced access to care and genetic testing, according to a study published in JAMA Cardiology. Continue reading →

Cholesterol-lowering statin medications have been at the forefront of managing cardiovascular disease for several decades now. Why? Its because a large body of research supports their benefits in reducing the risk of heart attack and stroke. Continue reading →

SHEBOYGAN, Wis., Jan. Continue reading →

La Porte and Starke Hospitals have announced their 2019 selections for Colleagues of the Year La Porte and Starke Hospitals have announced their 2019 selections for Colleagues of the Year, honoring individuals who were nominated both by patients and their peers for providing excellent, compassionate care and service to the community. Continue reading →

University of Maryland Shore Regional Health experienced significant progress in 2019 toward achieving our mission, "Creating Healthier Communities Together," and our vision, "To Be the Regions Leader in Patient Centered Health Care." As in years past, the amazing talent, steadfast commitment and highly engaged teamwork of the nearly 3,000 members of our UM SRH family enabled us to move forward in each of our key goals. Quality, Safety and Patient Experience Delivering a positive patient experience is our guiding principle at UM SRH. This is only possible in a healthy and collegial workplace environment Continue reading →

January 06, 2020 12:05 ET | Source: Novartis International AG Basel, January 6, 2020 Novartis AG (NYSE: NVS) (Novartis) today announced that it has completed the acquisition of The Medicines Company (the Company) through the consummation of a merger of its indirect wholly-owned subsidiary, Medusa Merger Corporation (Purchaser), with and into the Company, with the Company surviving the merger, without a vote of the Companys stockholders in accordance with Section 251(h) of the Delaware General Corporation Law. In the merger, each share of the Companys common stock outstanding immediately prior to the effective time of the merger (other than shares owned by Novartis, Purchaser, the Company, any other subsidiary of Novartis or any subsidiary of the Company, or shares that are held in the Companys treasury or shares held by any Company stockholder who has properly demanded and perfected appraisal rights under Delaware law) has been converted into the right to receive USD 85.00 per share, net to the seller in cash, without interest and subject to any tax withholding Continue reading →